Results 21 to 30 of about 1,662 (181)

Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats

Journal of Research in Medical Sciences, 2017
Background: To compare the efficacy of subconjunctival administration of bevacizumab and different doses of sunitinib malate in reducing corneal neovascularization (CNV).
Mohammad Nasser Hashemian, Hadi Z Mahrjerdi, Mehdi Mazloumi, Mona S Safizadeh, Yadollah Shakiba, Firouzeh Rahimi, Mohsen Afarideh, Mohamad Ali Zare, Mohammadreza Fallah Tafti, Bahram Bohrani Sepidan, Mohammad Ali Abtahi, Seyed-Hossein Abtahi   +11 more
doaj   +3 more sources

Management of Primary Pterygium with Intralesional Bevacizumab (AVASTIN) Injection

Pakistan Armed Forces Medical Journal, 2023
Objective: To determine the management of primary Pterygium with intralesional Bevacizumab (AVASTIN) Injection. Study Design: Quasi-Experimental Study Place and Duration of Study: Armed Forces Institute of Ophthalmology, Rawalpindi Pakistan, from ...
Irum Mahmood, Muhammad Shahid, Muhammad Awais, Muhammad Manzoor, Abdul Rauf, Zaheer Uddin Babar   +5 more
doaj   +3 more sources

Comparison of the inhibitory effect of different doses of subconjunctival bevacizumab application in an experimental model of corneal neovascularization [PDF]

International Journal of Ophthalmology, 2018
AIM: To evaluate the inhibitory effect of subconjunctival bevacizumab as single- and multiple-dose application, and compare their effects on corneal neovascularization in a rat model.
Burak Ulas, Rana Altan-Yaycioglu, Nebil Bal   +2 more
doaj   +3 more sources

Subconjunctival injection of bevacizumab for treatment of pterygium

Philippine Journal of Ophthalmology, 2009
Objective: This study determined the biologic effect and safety of subconjunctival administration of bevacizumab in patients with primary and recurrent pterygium. Methods: We conducted an off-label, multiple-dosing, interventional case series involving
Anthony F. Felipe, MD, Ruben Lim Bon Siong, MD, Harvey S. Uy, MD   +2 more
doaj   +1 more source

Subconjunctival bevacizumab to augment trabeculectomy with mitomycin C in the management of failed glaucoma surgery

Clinical Ophthalmology, 2014
Ahmed M Saeed, Tarek Tawfeek AboulNasrOphthalmology Department, Benha University, Egypt Purpose: To provide a feasible solution to the problem of failed glaucoma surgery.
Saeed AM, AboulNasr TT
doaj   +1 more source

Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab

Clinical Ophthalmology, 2014
Gian Maria Cavallini,1 Graziella Pellegrini,2 Veronica Volante,1 Pietro Ducange,1 Michele De Maria,1 Giulio Torlai,1 Caterina Benatti,1 Matteo Forlini1 1Institute of Ophthalmology, 2Centre for Regenerative Medicine “Stefano Ferrari&rdquo ...
Cavallini GM, Pellegrini G, Volante V, Ducange P, De Maria M, Torlai G, Benatti C, Forlini M   +7 more
doaj   +1 more source

Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma

Clinical Ophthalmology, 2011
Mohammad-Reza Sedghipour, Ali Mostafaei, Yousef TaghaviNikoukari Ophthalmology University Hospital, Tabriz University of Medical Sciences, Tabriz, IranBackground: The purpose of this study was to assess the effect of bevacizumab in maintaining ...
Sedghipour MR, Mostafaei A, Taghavi Y
doaj   +1 more source

Progressive anterior segment involvement of an infant with corneoscleral juvenile xanthogranuloma refractory to topical steroids [PDF]

American Journal of Ophthalmology Case Reports
Purpose: To report a case of corneoscleral juvenile xanthogranuloma (JXG) with progressive anterior segment involvement refractory to topical steroids. Observations: A 4-month-old male was referred for a new-onset subconjunctival lesion in the right eye.
Sanjana Suraneni, Charissa H. Tan, Lindsay M. Foley, Sander R. Dubovy, Basil K. Williams, Audina M. Berrocal, Ta Chen Chang, Angela Y. Zhu   +7 more
doaj   +2 more sources

Suppression of Neovascularization by Topical and Subconjunctival Bevacizumab After High-Risk Corneal Transplantation [PDF]

Ophthalmology Science
Purpose: To assess the effectiveness of topical and subconjunctival bevacizumab in suppressing vascularization in graft and host bed after high-risk corneal transplantation.
Thomas H. Dohlman, MD, Rohan Bir Singh, MD, Francisco Amparo, MD, Tatiana Carreno-Galeano, MD, Mohammad Dastjerdi, MD, Giulia Coco, MD, Antonio Di Zazzo, MD, Hasanain Shikari, MD, Ujwala Saboo, MD, Kimberly Sippel, MD, Jessica Ciralsky, MD, Sonia H. Yoo, MD, Matheus Sticca, MD, Tais H. Wakamatsu, MD, Somasheila Murthy, MD, Pedram Hamrah, MD, Ula Jurkunas, MD, Joseph B. Ciolino, MD, Hajirah Saeed, MD, MPH, Jose A.P. Gomes, MD, Victor L. Perez, MD, Jia Yin, MD, PhD, MPH, Reza Dana, MD, MPH   +22 more
doaj   +2 more sources

Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model

International Journal of Ophthalmology, 2013
AIM:To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition of corneal neovascularization in an experimental rat model.METHODS:Sixteen corneas of 16 rats were chemically cauterized and ...
Cem Küçükerdönmez, Veysi Öner, Ebru Eren Akar, Yonca Aydın Akova   +3 more
doaj   +3 more sources